Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007196
Chunk: 121

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 121
---
 securities offered by this prospectus.

We
understand that in England it may not be possible to bring proceedings or enforce a judgment of a U.S. court in respect of civil liabilities
based solely on the federal securities laws of the United States. In addition, awards of punitive damages in actions brought in the United
States or elsewhere may be unenforceable in England. An award of damages is usually considered to be punitive if it does not seek to compensate
the claimant for loss or damage suffered and is instead intended to punish the defendant. In addition to public policy aspects of enforcement,
such as the aforementioned, the enforceability of any judgment in England will depend on the particular facts of the case and the relevant
circumstances, for example (and expressly without limitation), whether there are any relevant insolvency proceedings which may affect
the ability to enforce a judgment. In addition, the United States and the United Kingdom have not currently entered into a treaty (or
convention) providing for the reciprocal recognition and enforcement of judgments (although both are contracting states to the New York
Convention on the Recognition and Enforcement of Foreign Arbitral Awards).

| 66 |

<div align='center'>WHERE YOU CAN FIND MORE INFORMATION</div>

We are subject to periodic
reporting and other informational requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, as applicable
to foreign private issuers. Accordingly, we are required to file reports, including annual reports on Form 20-F, and other information
with the SEC. As a foreign private issuer, we are exempt from the rules of the Exchange Act prescribing the furnishing and content of
proxy statements to shareholders under the federal proxy rules contained in Sections 14(a), (b) and (c) of the Exchange Act,
and our “insiders” are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of
the Exchange Act. The SEC maintains an Internet site that contains reports, proxy, information statements and other information regarding
issuers at http://www.sec.gov. Copies of certain information filed by us with the SEC are also available on our website at http://www.biodexapharma.com.
Our website is not a part of this prospectus and is not incorporated by reference in this prospectus.

This prospectus is part of
a registration statement we filed with the SEC. This prospectus omits some information contained in the registration statement in accordance
with SEC rules and regulations. You should review